secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001837607-24-000066
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma discontinues Phase 2 migraine study after failed endpoints; CFO terminated, CEO takes PFO role
--------------------------------------------------------------------------------

- Phase 2 double-blind migraine study (episodic and chronic cohorts) discontinued; chronic cohort failed primary and secondary endpoints.
- Open-label extension study also stopped; patients monitored for safety for 12 weeks post last treatment.
- CEO Marc Forth appointed principal financial officer after termination of CFO Peter Reynolds effective May 17, 2024.
- Jennifer Sy appointed principal accounting officer; no additional compensation for Forth or Sy.
- Company to conserve cash and evaluate strategic options after study discontinuation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000066/0001837607-24-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000066/aeon-20240516x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-24-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer